MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MAB Discovery GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11210
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats by employing biochemical and cellular based screens. It relies on natural immune response and B cell cloning techniques for the production of monoclonals with unprecedented epitope coverage and potency. MAB Discovery’s B-cells are cloned by fluorescence activated cell sorting and deposited as single cells into proprietary growth medium. It also undertakes projects from immunization, high throughput screening, assay development, and functional characterization. The company partners with biotech and pharmaceutical companies for the discovery and generation of monoclonal antibodies. MAB Discovery is headquartered in Neuried, Germany.

MAB Discovery GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Licensing Agreements 17
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH – Key Competitors 19
MAB Discovery GmbH – Key Employees 20
MAB Discovery GmbH – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Other Significant Developments 22
Jun 20, 2018: Ongoing discussions with MAB Discovery for revised collaboration agreement Advance notice of termination of existing agreement in-line with discussions 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Key Facts 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH, Key Competitors 19
MAB Discovery GmbH, Key Employees 20

List of Figures
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compania Minera Autlan SAB de CV:企業の戦略・SWOT・財務情報
    Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SONIFI Solutions, Inc:企業の戦略的SWOT分析
    SONIFI Solutions, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Akers Biosciences Inc (AKER):医療機器:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Mercuria Energy Group Ltd:企業のM&A・事業提携・投資動向
    Mercuria Energy Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercuria Energy Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • GP JOULE GmbH:電力:M&Aディール及び事業提携情報
    Summary GP JOULE GmbH (GP JOULE) is an alternative energy company that offers natural resource conservation solutions. The company offers products such as solar carports and movers, and green house systems. Its services include planning, engineering, procurement, and construction, operations, and ma …
  • AIA Bhd:企業の戦略・SWOT・財務情報
    AIA Bhd - Strategy, SWOT and Corporate Finance Report Summary AIA Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Bright Horizons Family Solutions LLC (BFAM):企業の財務・戦略的SWOT分析
    Summary Bright Horizons Family Solutions LLC (Bright Horizons) is a provider of educational advisory services and child care services. The company offers curriculum and programs including early education and preschool, back-up child and adult care programs, infant care, toddler care, college coach, …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • IMAX Corporation:企業のM&A・事業提携・投資動向
    IMAX Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IMAX Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Xbrane Biopharma AB (XBRANE):企業の財務・戦略的SWOT分析
    Summary Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products. The company's product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It combi …
  • Biowa Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biowa Inc (BioWa), a subsidiary of Kyowa Hakko Kirin Co Ltd (KHK), is a science and technology company that provides out licensing of therapeutic antibody technologies of KHK. The company also developes fucose free monoclonal antibodies that increase cellular cytotoxicity. Its technology inc …
  • Tereos SA:企業の戦略的SWOT分析
    Tereos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Seikagaku Corp (4548):企業の財務・戦略的SWOT分析
    Summary Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It also manufactures and markets pharmaceutical produ …
  • Wawa Inc:企業の戦略・SWOT・財務情報
    Wawa Inc - Strategy, SWOT and Corporate Finance Report Summary Wawa Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Western Gas Partners, LP:企業のM&A・事業提携・投資動向
    Western Gas Partners, LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Western Gas Partners, LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • CMA CGM SA:企業の戦略・SWOT・財務情報
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Global Blood Therapeutics Inc (GBT):製薬・医療:M&Aディール及び事業提携情報
    Summary Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company's lead drug candidate GBT440 is an oral, small molecule drug for the treatment o …
  • Petrogas E&P LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrogas E&P LLC (Petrogas), a subsidiary of MB Holding Company LLC, is an oil and gas company that offers crude oil exploration and development services. The company explores and produces crude oil, natural gas, and other petroleum products. It holds interest in oil producing areas in onsho …
  • Caterpillar Inc.:戦略・SWOT・企業財務分析
    Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report Summary Caterpillar Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆